Vertex (VRTX) Report Positive Data from Viral Kinetic of ALS-2200 in HCV Patients
Tweet Send to a FriendGet Alerts VRTX Hot Sheet
Up)
Trade VRTX Now!
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and its collaborator Alios BioPharma, Inc. today announced positive results from a viral kinetic study of the nucleotide analogue ALS-2200 for the treatment of hepatitis C. There was a median 4.54 log10 reduction in hepatitis C virus (HCV) RNA in people with genotype 1 chronic hepatitis C who were new to treatment (n=8) after seven days of dosing with 200 mg of ALS-2200 once daily. ALS-2200 was well-tolerated in this study, and no patients discontinued due to adverse events. Based on these data, Vertex plans to begin Phase 2 studies this year of 12-week all-oral regimens including ALS-2200 in people with genotype 1 hepatitis C, pending discussions with regulatory agencies.
Patients with hepatitis C dosed with ALS-2200 in this study had a dose-dependent, consistent and rapid decline in HCV RNA. After three days of dosing, a median 3.85 log10 decline was observed among patients in the 200 mg dose group. In this dose group, a median 4.54 log10 decline was observed after seven days of dosing, which was maintained for up to two days after the completion of dosing.
Based on these data, Vertex expects to conduct a study to evaluate ALS-2200 in combination with INCIVEK® (telaprevir), the company’s approved protease inhibitor for people with genotype 1 hepatitis C, and a study of ALS-2200 in combination with ribavirin. These studies will evaluate 12 total weeks of treatment with a primary endpoint of SVR12 (sustained viral response: undetectable hepatitis C virus 12 weeks after the end of treatment) in people with genotype 1 hepatitis C.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Patients with hepatitis C dosed with ALS-2200 in this study had a dose-dependent, consistent and rapid decline in HCV RNA. After three days of dosing, a median 3.85 log10 decline was observed among patients in the 200 mg dose group. In this dose group, a median 4.54 log10 decline was observed after seven days of dosing, which was maintained for up to two days after the completion of dosing.
Based on these data, Vertex expects to conduct a study to evaluate ALS-2200 in combination with INCIVEK® (telaprevir), the company’s approved protease inhibitor for people with genotype 1 hepatitis C, and a study of ALS-2200 in combination with ribavirin. These studies will evaluate 12 total weeks of treatment with a primary endpoint of SVR12 (sustained viral response: undetectable hepatitis C virus 12 weeks after the end of treatment) in people with genotype 1 hepatitis C.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Abbott (ABT) Receives CE Mark for XIENCE Coronary Stent System
- Nokia Siemens (NOK) (SI) Enhances Smart Wi-Fi, Launches 3G Femtocell Access Point
- Regeneron (REGN) and Genentech Strike Deal on Worldwide EYLEA Sales
Create E-mail Alert Related Categories
Corporate News, FDAComments
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
A Kinetic Person's Power
Kenneth Adrian Ellis on Jul 31, 2012 07:09 PMMark as Spam | Reply to this comment
Speaking of kinetic...Author Kenneth Adrian Ellis has a four(4)-part special power and "Bonus Feature" that is revealed to readers in: A Kinetic Person's Power, Sub Titled: Voice Command Ability Visit the following four(4) links in relation. [1st]A 1min:58sec. Professional Author Display Video with over 13,400 views...just search: Kenneth Adrian Ellis on www.YouTube.com .[2nd]The Press Release with over 2,900 views www.PRLog.org/10285981 [3rd] A fifteen(15) mintue "spot" on internet talk radio...just search: Kenneth Adrian Ellis on www.BlogTalkRadio.com [4th] Is the Facebook Fan Page... www.TinyUrl.com/Author-Kenneth-Ellis ,where you can "LIKE" it!